Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ASK: "THE LAST DON" OF MOMENTUM TRADES -- Ignore unavailable to you. Want to Upgrade?

To: Phatt Jake who wrote (8291)	3/4/1999 10:45:00 AM
From: Dave Gore	Respond to of 15987

"Our current BPH system is positioned to notably expand the $9 billion worldwide market for BPH treatment by encouraging more men to seek treatment, especially those with moderate symptoms," stated CELN President and CEO Spencer Volk. "We expect the current clinical studies to confirm the 'walk-in be treated, walk-out with total relief' nature of our out-patient BPH system. From the CELN press release They have an outpatient treatment for the $9 billion prostrate market. It means you don't have to go under the knife! Human testing is being done NOW in England they also have MIT (yes that MIT!) technology (yes, exclusive license!) to conduct under FDA approval (Yes, FDA approval), targeted heat technology to shrink and eradicate breast tumors. Remember with medical device approval, only 2 phases are required, not 3 phases with drugs. The cycle is nearly complete on the Prostate technology and testing (results probably before end of March), and the breast tumor tests are 3-4 months off. I would call Geoff Eiten, PR